Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Next Previous
Trial Profile

A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nu 3 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors Lakewood Amedex

Most Recent Events

  • 04 Dec 2017 According to a Lakewood-Amdex media release, positive top-line data from this trial will be presented at the LD MICRO Main Event.
  • 29 Sep 2017 According to a Lakewood Amedex media release, the company will present top-line data at the BioPharm America Conference 2017.
  • 27 Sep 2017 According to a Lakewood Amedex media release, Dr. Alexander Reyzelman is Principal Investigator of the study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top